Gilead Sciences, Inc. $GILD Stock Holdings Lifted by D.A. Davidson & CO.

D.A. Davidson & CO. lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 66,923 shares of the biopharmaceutical company’s stock after buying an additional 5,159 shares during the quarter. D.A. Davidson & CO.’s holdings in Gilead Sciences were worth $8,214,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Corundum Trust Company INC bought a new stake in Gilead Sciences in the 3rd quarter valued at about $26,000. Financial Consulate Inc. lifted its position in Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 109 shares during the last quarter. BOCHK Asset Management Ltd bought a new stake in Gilead Sciences in the 4th quarter valued at about $31,000. MTM Investment Management LLC lifted its position in Gilead Sciences by 176.0% in the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 176 shares during the last quarter. Finally, Vision Financial Markets LLC lifted its position in Gilead Sciences by 123.1% in the 4th quarter. Vision Financial Markets LLC now owns 290 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 160 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead completed the previously announced acquisition of Arcellx for ~$7.8B (cash + CVR), securing anito‑cel ahead of potential commercial launch — a clear strategic boost to Gilead’s cell‑therapy pipeline and commercial addressable market. Gilead Completes Acquisition of Arcellx
• Positive Sentiment: Technical analysts note GILD is retesting a long-term cup base breakout and could have significant upside if momentum holds — one firm projects as much as ~35% upside from current levels, which can attract momentum buyers. Gilead Crosses Critical Breakout Level
• Neutral Sentiment: Coverage noting the Arcellx close also flags that GILD recently tested near‑term technical support (around $128) and shows oversold momentum indicators — this can produce short‑term volatility even as the deal is digested. Blockonomi: Gilead Closes Arcellx Buyout
• Neutral Sentiment: Sector context: previews of Amgen’s Q1 and broader biotech ETF commentary provide mixed signals — positive drug growth themes offset by pricing pressure and biosimilar competition, which could moderate sector‑wide investor appetite. Amgen Q1 Preview
• Negative Sentiment: A shareholder resolution from AHF asks Gilead for greater transparency on patent exclusivities — this raises governance and IP‑risk scrutiny that could concern investors focused on long‑term revenue protections. AHF Shareholder Resolution

Gilead Sciences Stock Up 1.2%

NASDAQ GILD opened at $129.26 on Wednesday. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The company’s 50 day simple moving average is $141.38 and its 200 day simple moving average is $132.39. Gilead Sciences, Inc. has a 12 month low of $95.29 and a 12 month high of $157.29. The company has a market capitalization of $160.44 billion, a P/E ratio of 19.09, a PEG ratio of 1.69 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the previous year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 8.62 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.5%. The ex-dividend date was Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio is presently 48.45%.

Analyst Ratings Changes

A number of analysts have recently weighed in on GILD shares. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, February 11th. Truist Financial raised their price objective on shares of Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Wall Street Zen upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 14th. Finally, Barclays began coverage on shares of Gilead Sciences in a research note on Friday, February 20th. They set an “equal weight” rating and a $155.00 price objective on the stock. Twenty-four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $157.35.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the transaction, the chief financial officer directly owned 176,191 shares of the company’s stock, valued at approximately $24,835,883.36. The trade was a 1.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $144.79, for a total value of $1,447,900.00. Following the completion of the sale, the chief executive officer directly owned 642,308 shares of the company’s stock, valued at approximately $92,999,775.32. This represents a 1.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 168,640 shares of company stock valued at $25,292,650 in the last three months. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.